Compare ERH & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ERH | RLYB |
|---|---|---|
| Founded | 2004 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 107.4M | 86.6M |
| IPO Year | N/A | 2021 |
| Metric | ERH | RLYB |
|---|---|---|
| Price | $11.60 | $16.54 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 21.7K | 19.8K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 8.85% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 6.16 |
| Revenue | N/A | ★ $858,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $2.69 |
| Revenue Growth | N/A | ★ 43.00 |
| 52 Week Low | $11.50 | $0.48 |
| 52 Week High | $13.07 | $17.57 |
| Indicator | ERH | RLYB |
|---|---|---|
| Relative Strength Index (RSI) | 37.70 | 56.64 |
| Support Level | $11.54 | $15.68 |
| Resistance Level | $11.96 | $17.34 |
| Average True Range (ATR) | 0.10 | 0.49 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 4.49 | 58.67 |
Allspring Utilities and High Income Fund is a diversified closed-end management investment company. Its investment objective is to seek a high level of current income and moderate capital growth, with an emphasis on providing tax-advantaged dividend income. The company allocates a majority of its total assets to a sleeve that places a focus on common, preferred, and convertible preferred stocks of utility companies and the rest of its total assets to a sleeve of U.S. dollar denominated below investment grade (high yield) debt.
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.